BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8103958)

  • 1. The use of surgery for the treatment of prolactinomas.
    van't Verlaat JW
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():34-7. PubMed ID: 8103958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Criteria for medical as opposed to surgical treatment of prolactinomas.
    Besser M
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():27-30. PubMed ID: 8103956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
    Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of resistant prolactinomas.
    Olafsdottir A; Schlechte J
    Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of prolactinoma with a new dopamine agonist].
    Svoboda T; Luger A; Knosp E; Geyer G
    Dtsch Med Wochenschr; 1991 Aug; 116(33):1224-7. PubMed ID: 1678695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
    Barnett PS; Palazidou E; Miell JP; Coskeran PB; Butler J; Dawson JM; Maccabe J; McGregor AM
    Q J Med; 1991 Nov; 81(295):891-906. PubMed ID: 1687293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy of prolactinomas.
    Jaquet P
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():31-3. PubMed ID: 8103957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
    Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
    Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the Leksell gamma knife in the treatment of prolactinoma patients.
    Jezková J; Hána V; Krsek M; Weiss V; Vladyka V; Liscák R; Vymazal J; Pecen L; Marek J
    Clin Endocrinol (Oxf); 2009 May; 70(5):732-41. PubMed ID: 18710463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?
    Turner HE; Adams CB; Wass JA
    Eur J Endocrinol; 1999 Jan; 140(1):43-7. PubMed ID: 10037250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Giant invasive prolactinoma: a case report and review of nine further cases.
    Davis JR; Sheppard MC; Heath DA
    Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of extensively invasive (giant) prolactinomas with bromocriptine.
    Grebe SK; Delahunt JW; Feek CM
    N Z Med J; 1992 Apr; 105(931):129-31. PubMed ID: 1560924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microprolactinomas in males treated by transsphenoidal surgery.
    Wolfsberger S; Czech T; Vierhapper H; Benavente R; Knosp E
    Acta Neurochir (Wien); 2003 Nov; 145(11):935-40; discussion 940-1. PubMed ID: 14628197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
    Duranteau L; Chanson P; Lavoinne A; Horlait S; Lubetzki J; Kuhn JM
    Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of macroprolactinomas at Auckland Hospital 1975-91.
    Wallace EA; Holdaway IM
    N Z Med J; 1995 Feb; 108(994):50-2. PubMed ID: 7885646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The treatment of prolactinoma].
    Serri O; Somma M; Beauregard H; Rasio E; Comtois R; Aris-Jilwan N; Boucher A; Hardy J
    Union Med Can; 1993; 122(6):496-9. PubMed ID: 7905686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
    Kars M; Pereira AM; Smit JW; Romijn JA
    Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.